Last updated: August 25, 2026
Prasugrel is a mature oral P2Y12 platelet inhibitor marketed primarily as Effient in the United States and Efient in several international markets. Its commercial profile has shifted from branded hospital and cardiology adoption to generic competition. The product retains clinical relevance for selected patients with acute coronary syndrome undergoing percutaneous coronary intervention, but its financial trajectory is constrained by generic erosion, competition from ticagrelor and clopidogrel, and a limited addressable population because of bleeding risks and contraindications.
What is the current FDA status of prasugrel?
The FDA approved Effient, prasugrel hydrochloride, on July 10, 2009, for reducing thrombotic cardiovascular events in patients with acute coronary syndrome managed with percutaneous coronary intervention. The product is approved for unstable angina, non-ST-elevation myocardial infarction, and ST-elevation myocardial infarction in the PCI setting.[1]
The standard maintenance dose is 10 mg once daily after a 60 mg loading dose. A 5 mg maintenance dose may be considered for patients weighing less than 60 kg. Prasugrel carries a boxed warning concerning significant and potentially fatal bleeding.[1]
Key FDA milestones
| Milestone |
Date |
Commercial significance |
| FDA approval of Effient |
July 10, 2009 |
Established prasugrel as a branded PCI antiplatelet |
| New chemical entity exclusivity |
2009-2014 |
Delayed FDA approval of competing products based on the active ingredient |
| Generic prasugrel approvals |
Beginning in 2017 |
Opened the U.S. market to price competition |
| Current product status |
Approved, genericized |
Brand retains limited value in contracting, institutional access, and residual prescribing |
Prasugrel is a small-molecule drug. It is not subject to biosimilar competition. The relevant threat is generic substitution under the abbreviated new drug application pathway.
What patents protect prasugrel and Effient?
The core prasugrel patent estate has largely expired in the United States. Early patents covering thienopyridine compounds and prasugrel-related chemistry were filed in the 1990s. Their effective commercial protection ended before or around the launch period, leaving regulatory exclusivity and later formulation or solid-state patents as the principal barriers to generic entry.
The central U.S. patent history includes patents assigned to Sankyo, now part of Daiichi Sankyo, covering thienopyridine derivatives and related pharmaceutical compositions. The original compound patent family did not provide long post-approval protection because of the timing of discovery, filing, grant, and statutory patent-term rules.
Prasugrel patent protection by category
| Patent category |
Typical scope |
Commercial status |
| Core compound patents |
Prasugrel molecule and related thienopyridine derivatives |
Expired or no longer commercially blocking in the U.S. |
| Salt and crystalline-form patents |
Prasugrel hydrochloride, polymorphs, and solid-state forms |
Limited relevance after generic approvals |
| Formulation patents |
Tablet composition, stability, or dosage presentation |
Narrower than compound protection |
| Method-of-use patents |
Treatment of ACS patients undergoing PCI |
Potentially relevant to labeling and litigation, but difficult to enforce against broad generic substitution |
| Manufacturing patents |
Synthesis, intermediates, purification, and crystallization |
May raise process costs without blocking non-infringing generic manufacture |
The Orange Book is the controlling commercial reference for FDA-listed patents and exclusivities. Effient's practical loss of U.S. exclusivity is demonstrated by the FDA's approval of generic prasugrel products, not by brand sales alone.[2]
When did prasugrel lose exclusivity?
Prasugrel lost effective U.S. market exclusivity in the late 2010s. FDA-approved generic prasugrel products entered after the five-year new chemical entity exclusivity period and after the relevant patent barriers had expired or become nonblocking.
Exclusivity timeline
| Period |
Event |
Effect on market |
| 2009 |
Effient approved |
Branded monopoly begins |
| 2009-2014 |
Five-year NCE exclusivity |
FDA could not approve an ANDA relying on prasugrel's full innovator dossier |
| 2014 onward |
Regulatory exclusivity ends |
ANDA filings become viable, subject to patents |
| 2017 onward |
Generic prasugrel approvals and launches |
Brand pricing power declines |
| 2020s |
Mature generic market |
Volume remains, but revenue is primarily generic and contract driven |
The precise first commercial launch date can vary by manufacturer, supply agreement, and dosage strength. The strategic conclusion is consistent: prasugrel is no longer a protected U.S. branded-growth product.
Which companies market prasugrel?
Daiichi Sankyo developed prasugrel and commercialized it with Eli Lilly in the United States. Daiichi Sankyo has retained major rights outside the United States, while Lilly held U.S. commercial responsibility for Effient.
Generic prasugrel has been supplied by multiple manufacturers, including companies operating through ANDA approvals and commercial distribution arrangements. The product's generic supply base can change as manufacturers enter, exit, or revise capacity.
Principal commercial participants
| Company |
Role |
| Daiichi Sankyo |
Originator and global rights holder in major markets |
| Eli Lilly |
U.S. development and commercialization partner for Effient |
| Teva and other generic manufacturers |
Generic prasugrel supply in the U.S. and international markets |
| Hospital distributors and group purchasing organizations |
Important channels for institutional purchasing |
Prasugrel is primarily an institutional and specialist product. Purchasing decisions are influenced by hospital formularies, cardiology protocols, payer substitution rules, discharge medication programs, and emergency department availability.
How has prasugrel revenue changed over time?
Effient revenue followed a typical branded cardiovascular trajectory. Sales increased after launch as clinicians adopted prasugrel for PCI patients, reached a mid-life peak, and declined as generic competition and newer P2Y12 inhibitors expanded.
Lilly reported Effient as a distinct or identifiable product in earlier annual reports. Reported sales declined materially over time as the product moved from branded growth to mature-market competition.[3] Daiichi Sankyo's reporting generally aggregates products by geographic region or business segment, limiting the availability of a single global prasugrel revenue series.[4]
Financial trajectory
| Stage |
Approximate period |
Financial pattern |
| Launch and adoption |
2009-2011 |
Rapid uptake in interventional cardiology |
| Expansion |
2012-2014 |
Broader use in ACS and PCI protocols |
| Mature branded phase |
2014-2016 |
Revenue pressure from competing antiplatelets and safety concerns |
| Generic transition |
2017-2019 |
Sharp decline in U.S. brand economics |
| Mature generic phase |
2020 onward |
Low-margin, volume-dependent business |
The key revenue exposure is no longer the absolute size of the antiplatelet market. It is the share of treated PCI patients for whom clinicians continue to select prasugrel over clopidogrel or ticagrelor, and the extent to which that volume is captured by generic manufacturers.
What drives prasugrel demand?
Prasugrel demand is concentrated in acute coronary syndrome patients undergoing PCI, particularly those in whom rapid and potent platelet inhibition is desired.
The product's clinical positioning was established by the TRITON-TIMI 38 trial. Compared with clopidogrel, prasugrel reduced ischemic events in the trial population but increased major bleeding, including fatal bleeding. Patients with a prior stroke or transient ischemic attack are contraindicated, and patients aged 75 years or older generally have an unfavorable risk-benefit profile except in selected high-risk circumstances.[1,5]
Principal demand drivers
- PCI procedure volumes.
- Acute coronary syndrome incidence.
- Hospital adoption of prasugrel-based protocols.
- Preference for a once-daily oral agent after loading.
- Clinical concern about clopidogrel response variability.
- Generic pricing and formulary availability.
- Use in younger or higher-thrombotic-risk PCI patients without prior cerebrovascular events.
Demand is structurally limited by bleeding risk. Prasugrel is not a universal replacement for clopidogrel and does not occupy the same broad maintenance market.
How does prasugrel compare with clopidogrel and ticagrelor?
Prasugrel competes against two commercially important P2Y12 inhibitors: generic clopidogrel and branded or genericizing ticagrelor. The products differ in potency, reversibility, dosing, safety, and cost.
| Attribute |
Prasugrel |
Clopidogrel |
Ticagrelor |
| Drug class |
Thienopyridine P2Y12 inhibitor |
Thienopyridine P2Y12 inhibitor |
Reversible P2Y12 inhibitor |
| Activation |
Prodrug |
Prodrug |
Active drug |
| Typical PCI loading dose |
60 mg |
300-600 mg |
180 mg |
| Maintenance dosing |
Once daily |
Once daily |
Twice daily |
| Main strength |
Potent platelet inhibition in selected PCI patients |
Low cost and broad familiarity |
Potent inhibition without metabolic activation |
| Main limitation |
Bleeding risk; contraindication after stroke/TIA |
Variable response and slower onset |
Twice-daily dosing, dyspnea, cost |
| Commercial status |
Generic mature market |
Fully generic |
Branded and generic competition developing |
Prasugrel's strongest commercial position is among PCI patients for whom clinicians prioritize potency and adherence simplicity but consider ticagrelor's twice-daily regimen or tolerability disadvantages undesirable. Its weakest position is in broad secondary prevention, elderly populations, prior stroke/TIA patients, and price-sensitive formularies.
What generic entry risks exist for prasugrel?
Generic substitution is the principal commercial risk. Because prasugrel is an oral small molecule with a conventional tablet presentation, the technical barrier to ANDA development is relatively low.
Generic entry effects
Generic entry affects prasugrel through:
- Lower average selling prices.
- Pharmacy-level substitution.
- Hospital formulary replacement.
- Reduced promotional return on investment.
- Greater dependence on manufacturing scale and supply reliability.
- Declining brand reimbursement and contracting leverage.
Generic manufacturers do not need to reproduce the originator's clinical development program. They generally demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug. This lowers development cost and accelerates price competition.
The remaining barriers are commercial rather than scientific. Manufacturers must secure reliable active pharmaceutical ingredient supply, meet FDA manufacturing requirements, qualify tablet production, and maintain inventory for hospital and retail channels.
Are there Paragraph IV challenges and prasugrel patent lawsuits?
Prasugrel faced the standard ANDA patent-challenge framework as generic companies sought FDA approval. Paragraph IV certifications may challenge listed patents as invalid, unenforceable, or not infringed. Once the relevant Orange Book patents expired or ceased to block approval, the commercial importance of such disputes declined.
Publicly visible litigation has been less commercially consequential than the patent litigation associated with major blockbuster products such as clopidogrel. The reason is the age of the prasugrel molecule and the limited duration of meaningful remaining patent protection at the time generic filings became commercially relevant.
Litigation assessment
| Issue |
Assessment |
| Core molecule patent challenge |
Low current significance because core protection has expired |
| Formulation patents |
Potentially relevant but narrow |
| Method-of-use patents |
Enforcement may be complicated by label design and physician prescribing |
| Paragraph IV litigation |
Relevant during generic approval strategy, less important after patent expiry |
| Settlement risk |
Low current impact on market access |
| Current injunction risk |
Low relative to the period before generic entry |
A generic manufacturer can often avoid method-of-use exposure through a skinny label that omits patented indications, where permitted by FDA labeling rules. Prasugrel's principal approved use is closely tied to ACS and PCI, which can narrow the practical value of label carve-outs, but the remaining patent landscape is not comparable to an active compound patent estate.
What is the Orange Book status of Effient?
Effient is listed in the FDA's Orange Book as the reference product for generic prasugrel tablets. Orange Book entries determine the patents and exclusivities that ANDA applicants must address at the time of filing.[2]
The commercial status is mature:
- Effient is no longer protected by meaningful U.S. NCE exclusivity.
- Generic prasugrel products have received FDA approval.
- The active commercial issue is substitution and reimbursement, not regulatory exclusivity.
- Any remaining listed patent must be assessed by strength, expiry, dosage form, and relevance to the proposed generic label.
The Orange Book does not by itself measure commercial patent strength. A listed patent can have limited practical value if it is narrow, expired soon, vulnerable to invalidity arguments, or avoidable through a non-infringing formulation.
How strong is the prasugrel patent estate?
The current prasugrel patent estate is weak as a barrier to U.S. generic competition and moderate only for selected manufacturing or formulation claims.
Patent-strength assessment
| Dimension |
Strength |
Business implication |
| Core composition of matter |
Low |
No durable U.S. monopoly |
| Salt and polymorph protection |
Low to moderate |
May affect specific products but rarely supports broad exclusion |
| Tablet formulation |
Low |
Conventional dosage form is difficult to defend broadly |
| Method of use |
Low to moderate |
Possible label and enforcement leverage |
| Manufacturing process |
Moderate in isolated cases |
Can raise costs but generally does not block alternative processes |
| International coverage |
Variable |
Depends on country-specific expiry and local generic approval rules |
Daiichi Sankyo and Lilly cannot use the historical brand position to recreate broad U.S. exclusivity. The value of any remaining intellectual property is therefore defensive or incremental rather than transformational.
What licensing deals affected prasugrel?
The principal commercial transaction was the collaboration between Daiichi Sankyo and Eli Lilly for development and commercialization of prasugrel. The agreement gave Lilly a major role in the United States while Daiichi Sankyo maintained broader international commercial interests.[6]
The partnership created a multinational launch infrastructure but also divided future economics. After generic entry, the value of the collaboration shifted from growth-stage promotion to management of residual brand demand and regional rights.
No new licensing structure is needed to sustain a mature generic prasugrel market. Potential deal value is concentrated in regional distribution, hospital supply, authorized-generic arrangements, or combination products rather than in a new global branded launch.
What is the international market outlook for prasugrel?
Prasugrel's geographic opportunity is uneven. Japan remains strategically relevant to Daiichi Sankyo, which commercializes Efient in its home market. The United States is a mature generic market. Europe and other developed markets have experienced price pressure and varying levels of adoption based on treatment guidelines, reimbursement, and local generic penetration.
Geographic commercial profile
| Region |
Market condition |
| United States |
Genericized; brand economics limited |
| Japan |
Originator-backed market with continuing clinical use |
| Europe |
Mature market with country-specific reimbursement and generic competition |
| Emerging markets |
Volume opportunity, but low prices and local competition |
| Hospitals globally |
Important channel because treatment begins in acute-care settings |
Geographic coverage is therefore a volume strategy rather than a high-margin exclusivity strategy. Manufacturing and supply reliability can matter more than patent protection in low-price markets.
What is the outlook for prasugrel revenue?
Prasugrel revenue should remain stable to declining in aggregate, with generic volume offsetting part of the decline in branded value. The product is unlikely to return to blockbuster economics without a new indication, differentiated formulation, or major change in treatment guidelines.
The main financial variables are:
- PCI procedure growth.
- Generic price compression.
- Retention of institutional formulary access.
- Use among patients under 75 years old without prior stroke or TIA.
- Competition from ticagrelor.
- Continued clinical preference for once-daily dosing.
- Supply and tender wins in Japan and other regulated markets.
For originator companies, prasugrel is a residual or portfolio product. For generic manufacturers, it is a low- to mid-value cardiovascular product whose attractiveness depends on manufacturing efficiency, stable API access, and limited market crowding.
What generic launch scenarios are most likely?
Scenario 1: Continued price erosion
This is the base case. Multiple generic suppliers compete for a stable but limited PCI-related patient population. Brand share falls, while generic volume increases and per-unit revenue declines.
Scenario 2: Stable specialist niche
Prasugrel retains a defined role in younger, high-risk PCI patients. Generic prices stabilize after initial erosion, and manufacturers with dependable supply preserve share.
Scenario 3: Further clinical displacement
Ticagrelor or evolving guideline preferences reduce prasugrel use, especially where clinicians favor reversible inhibition or broader ACS indications. This scenario would produce declining volume as well as price pressure.
Scenario 4: Regional resilience
Japan or selected international markets sustain originator sales through local reimbursement, brand familiarity, or lower generic penetration. Regional resilience would not materially change the U.S. financial outlook.
Key Takeaways
- Prasugrel is an established oral P2Y12 inhibitor approved by the FDA for ACS patients undergoing PCI.
- Effient's U.S. exclusivity ended in practical terms when generic prasugrel products entered from 2017 onward.
- The core patent estate is expired or commercially nonblocking; remaining formulation, method-of-use, and manufacturing patents provide limited protection.
- The product's clinical advantage is potent, once-daily platelet inhibition in selected PCI patients.
- Bleeding risk, prior stroke or TIA contraindication, and age-related limitations restrict the addressable market.
- Generic substitution is the dominant commercial force.
- Daiichi Sankyo and Lilly's branded revenue trajectory peaked during the 2010s and declined after generic entry.
- Prasugrel has no biosimilar risk because it is a small molecule.
- Future value depends on generic manufacturing economics, hospital formulary retention, Japanese and international demand, and competition from ticagrelor.
- A return to large branded revenue is unlikely without a new indication or differentiated delivery technology.
FAQs
Is prasugrel still sold under the Effient brand?
Yes. Effient remains the reference product, but generic prasugrel is available and has materially reduced the brand's commercial leverage.
Can patients with a prior stroke take prasugrel?
Prasugrel is contraindicated in patients with a history of stroke or transient ischemic attack because of the risk of serious bleeding.[1]
Is prasugrel more potent than clopidogrel?
In the PCI population studied in TRITON-TIMI 38, prasugrel produced stronger platelet inhibition and reduced ischemic events relative to clopidogrel, but increased major bleeding.[5]
Does prasugrel have a biosimilar competitor?
No. Biosimilar legislation applies to biologic products. Prasugrel competes with chemically synthesized generic tablets.
What would most improve prasugrel's commercial outlook?
A differentiated formulation, validated benefit in a new patient group, or a guideline change favoring prasugrel could improve demand. Patent-based recovery of broad U.S. exclusivity is not a realistic commercial scenario.
References
-
U.S. Food and Drug Administration. (2024). Effient (prasugrel hydrochloride) prescribing information. FDA.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
-
Eli Lilly and Company. (2011-2018). Annual reports and Form 10-K filings. Eli Lilly and Company.
-
Daiichi Sankyo Company, Limited. (2011-2024). Annual reports and financial results. Daiichi Sankyo.
-
Wiviott, S. D., Braunwald, E., McCabe, C. H., Montalescot, G., Ruzyllo, W., Gottlieb, S., Neumann, F. J., Ardissino, D., De Servi, S., Murphy, S. A., Riesmeyer, J., Weerakkody, G., Gibson, C. M., Antman, E. M., & TRITON-TIMI 38 Investigators. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. New England Journal of Medicine, 357(20), 2001-2015.
-
Eli Lilly and Company. (2007). Daiichi Sankyo and Eli Lilly announce global alliance for prasugrel. Corporate transaction announcement.
